Live Breaking News & Updates on Hackensack meridian health oncology care transformation services

Stay updated with breaking news from Hackensack meridian health oncology care transformation services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

Andre-goy , Lydia-pfund , Hackensack-meridian-health-oncology-care-transformation-services , Hackensack-meridian-school-of-medicine , John-theurer-cancer-center , Lymphoma-division , Georgetown-university , Hackensack-university-medical-center , Lydia-pfund-chair , Hackensack-meridian-school ,

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

United-states , Andre-goy , Hackensack-meridian-health-oncology-care-transformation-services , John-theurer-cancer-center , Lymphoma-division , Hackensack-university-medical-center , John-theurer-cancer-center , Ackensack-university-medical-center , Onclive-tv , Mantle-cell-lymphoma ,

'Remarkable' Results from Tecartus in Patients With R/R MCL

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

United-states , American , Andre-goy , American-society-of-hematology , Drug-administration , John-theurer-cancer-center , Hackensack-university-medical-center , Hackensack-meridian-health-oncology-care-transformation-services , Annual-meeting , Mantle-cell-lymphoma ,

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre-goy , John-theurer-cancer-center , Hackensack-meridian-health-oncology-care-transformation-services , Hackensack-university-medical-center , Lymphoma-division , Ash-annual-meeting-and-exposition , Onclive-tv , Conference- , Mantle-cell-lymphoma , Mcl , Ash-2023 ,

Dr Goy on the Influence of High-Risk Features on Treatment Decision-Making in MCL

Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.

Andre-goy , International-prognostic-index , Lymphoma-division , Hackensack-university-medical-center , John-theurer-cancer-center , Hackensack-meridian-health-oncology-care-transformation-services , Prognostic-index , Genetic-abnormalities , Mantle-cell-lymphoma , High-risk-features ,

Refining Treatment Approaches Remains a Priority in High-Risk MCL

Andre Goy, MD, discusses the agents that are currently available for the treatment of patients with relapsed/refractory mantle cell lymphoma, explains the prevalence of high-risk features in this population, and emphasizes the importance of enrolling patients into clinical trials to move the needle forward.

Hackensack , New-jersey , United-states , Andre-goy , International-prognostic-index , Hackensack-meridian-health-oncology-care-transformation-services , Lymphoma-division , John-theurer-cancer-center , Hackensack-university-medical-center , Prognostic-index , D , Mantle-cell-lymphoma

Applied Molecular Medicine Signals the Future of Personalized, Preventive Cancer Care

Andre Goy, MD, discusses advances in the field of oncology that prompted the development of the Hennessy Institute, how early cancer detection can improve patient outcomes, and the importance of employing accessible cancer prevention strategies.

New-jersey , United-states , Hackensack , Andre-goy , Hennessy-institute-for-cancer-prevention , Hackensack-meridian-health-oncology-care-transformation-services , Hennessy , Mike-patti-hennessy-foundation , Hennessy-institute , Hackensack-meridian-school-of-medicine , Hennessey-institute , Hackensack-meridian-john-theurer-cancer-center